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Gestational trophoblastic neoplasms (GTNs) are a rare group of neoplastic diseases composed of choriocarcinomas, placental site
trophoblastictumors(PSTTs)andepithelioidtrophoblastictumors(ETTs).Sincethesetumorsarederivativesoffetaltrophoblastic
tissue, approximately 50% of GTN cases are expected to originate from a male conceptus and carry a Y-chromosomal complement
according to a balanced sex ratio. To investigate this hypothesis, we carried out a comprehensive analysis by genotyping a relatively
large sample size of 51 GTN cases using three independent sex chromosome genetic markers; Amelogenin, Protein Kinase and
Zinc Finger have X and Y homologues that are distinguishable by their PCR product size. We found that all cases contained
the X-chromosomal complement while only ﬁve (10%) of 51 tumors harbored the Y-chromosomal complement. Speciﬁcally, Y-
chromosomal signals were detected in one (5%) of 19 choriocarcinomas, one (7%) of 15 PSTTs and three (18%) of 17 ETTs. The
histopathological features of those with a Y-chromosome were similar to those without. Our results demonstrate the presence of
a Y-chromosomal complement in GTNs, albeit a low 10% of cases. This shortfall of Y-chromosomal complements in GTNs may
reinforce the notion that the majority of GTNs are derived from previous molar gestations.
1.Introduction
Gestational trophoblastic neoplasms (GTNs) represent a
unique group of human tumors that develop as a semial-
lograft from fetus-derived tissues [1]. GTNs were originally
consideredahomogeneousgroupofdiseasesarisingfromthe
neoplastic transformation of trophoblastic cells. However,
recent clinicopathological studies have provided evidence
that there are at least three distinctive types of GTNs
including the most common type, choriocarcinomas, and
the less common placental site trophoblastic tumors (PSTTs)
and epithelioid trophoblastic tumors (ETTs). GTNs have
been proposed to develop from trophoblastic stem cells, pre-
sumably the cytotrophoblastic cells, and the patterns of dif-
ferentiation in GTNs recapitulate the early stages of placental
development [1]. According to this view, choriocarcinomas
are composed of variable amounts of neoplastic cytotro-
phoblasts, syncytiotrophoblasts, and extravillous (interme-
diate) trophoblasts, resembling the previllous blastocyst
which is composed of a similar mixture of trophoblastic
subpopulations. In contrast, the neoplastic cytotrophoblasts
inPSTTsdiﬀerentiatemainlyintoextravillous(intermediate)
trophoblastic cells; whereas the neoplastic cytotrophoblasts
in ETTs diﬀerentiates into chorionic-type extravillous (inter-
mediate) trophoblastic cells. According to this model, chori-
ocarcinomas are the most primitive trophoblastic tumors,
whereas PSTTs and ETTs are relatively more diﬀerentiated.
Clinically, choriocarcinoma is a highly malignant epithe-
lial tumor arising from the trophoblasts of any type of
gestational event, most often a complete hydatidiform mole
[2]. Patients are in their reproductive age and present
with abnormal vaginal bleeding and occasionally signs of
distantmetastasis.Microscopically,itpredominantlyconsists
of a biphasic proliferation of mononucleate trophoblasts2 Journal of Oncology
and syncytiotrophoblasts, accompanied by prominent hem-
orrhage and necrosis [3]. With the advent of modern
chemotherapy, the overall survival for patients with chori-
ocarcinomas currently approaches 100% [4] although some
patients develop nonoperable and chemoresistant recurrent
disease. As compared to choriocarcinomas, PSTTs and ETTs
are rare [5–7]. Like choriocarcinomas, PSTTs and ETTs
occur in women of reproductive age and present with
either amenorrhea or abnormal bleeding [5, 7, 8]. Despite
deep myometrial invasion, most cases of PSTTs and ETTs
are successfully treated [2] but approximately 10–15% are
clinically malignant and have a fatal outcome. Histologically,
PSTTs are characterized by masses or sheets of intermediate
trophoblastic cells resembling implantation site intermediate
trophoblasts, while ETTs are characterized by chorionic-
type intermediate trophoblasts of the normal implantation
site and placenta. In addition to distinct morphological
features, both PSTTs and ETTs are characterized by unique
gene expression patterns, suggesting that the molecular
pathogeneses of PSTTs and ETTs are dissimilar [9].
Hydatidiform moles [10, 11] are precursor lesions of
numerous cases of GTNs. Previous clinicopathological and
molecular studies have provided fundamental insight into
the pathogenesis of hydatidiform moles but the molecular
and cellular basis for the development of GTNs remain
poorly understood. A similar number of GTN cases with and
without a Y-chromosome are expected if sex chromosomes
play no role in the development of GTNs. On the contrary,
more than 85% of patients with PSTTs were found by history
records or genetic analysis to have had a female antecedent
gestation. Moreover, a recent study using the Amelogenin
assay demonstrated the presence of a X-chromosome and
absence of a Y in a small series of PSTTs [12], raising
the possibility that a Y-chromosomal complement may be
preferentially deleted in PSTTs. In this paper we describe our
ﬁndings in a larger number of PSTTs, as well as other types
of GTNs including choriocarcinomas and ETTs. In addition,
unlike previous studies using a single marker, we examined
a total of three genetic markers including the commonly
used amelogenin. These genes have X and Y homologues
that can be distinguished by their polymerase chain reaction
(PCR) product sizes using speciﬁc primer pairs, to detect the
presence of a Y allele.
2. Methods
2.1. Tissue Specimens. Paraﬃn tissues from a total of 51
GTNs were retrieved from the archival ﬁles in the Depart-
ment of Pathology at the Johns Hopkins Hospital, USA.
Most of the specimens were consultation cases sent to two
of the authors (R. J. Kurman and I. M. Shih). Hematoxylin
and eosin stained sections from tissue specimens were
reviewed and the diagnosis of speciﬁc types of GTNs were
conﬁrmed by an expert gynecologic pathologist (I. M.
Shih). The specimens included 15 PSTTs, 17 ETTs, and
19 choriocarcinomas. All the specimens were anonymized
and thus clinical information was not obtained. Tissues
collection was conducted in compliance with institutional
Table 1: The primer sequences used to amplify the PRK and ZF
loci.
Primer
Name Sequence
PRK-F 5  FAM-TTTTGTTTCTTTCTGTCCATACTTAAAG 3 
PRK-R 5  TCCCAAACCACTCAACTG 3 
ZF-F 5  FAM-TGTGCATAACTTTGTTCCTGATG 3 
ZF-R 5  AGCACTTGCTCAGGAATGATG 3 
review board regulations. The tumor areas on paraﬃns e c -
tions were carefully dissected from the surrounding normal
(maternal) tissues on hematoxylin-stained tissue sections.
Genomic DNA was prepared by using the Formapure kit
(Agencourt, Cambridge, MA). One representative tissue
block was selected for DNA extraction except for ﬁve cases in
which the DNA was puriﬁed from two separate tissue blocks.
2.2. Genotyping Using Sex Chromosome-Speciﬁc Genetic
Markers. The presence of either a X or a Y-chromosome in
GTNs was determined by the analysis of three genes that
have X and Y-chromosomal homologues distinguishable by
their PCR product size with speciﬁc primer sets; Amelogenin
X and Y (AMELX and AMELY), Protein Kinase Xa n d
Y( PRKX and PRKY), and Zinc Finger Xa n dY( ZFX
and ZFY). The amelogenin gene has X and Y homologues
located on Xp22.1–22.3 (AMELX) and Yp11.2 (AMELY),
which are diﬀerentiated using a primer pair that ampliﬁes
a region of intron 1 which spans a 6-base pair deletion in
AMELX as compared to AMELY. The Amelogenin analysis
was performed using the commercially available AmpFlSTR
Proﬁler kit (Applied Biosystems, Foster City, CA). Thermal
cycling conditions and capillary electrophoresis were carried
out according to the manufacturer’s instructions. Brieﬂy, the
PCR conditions were 95◦C for 11 minutes followed by 28
cycles of 94◦Cf o r1m i n u t e ,5 9 ◦Cf o r1m i n u t e ,a n d7 2 ◦C
for 1 minute, followed by a ﬁnal extension at 60◦Cf o r4 5
minutes. After ampliﬁcation, capillary electrophoresis was
carried out using 1µl of multiplex PCR product, mixed
with 9µl of deionized formamide/GeneScan 500 (ROX)
size standard (Applied Biosystems). Samples were then
denatured at 95◦C for 2 minutes before analysis on the
ABI3100 Genetic Analyzer (Applied Biosystems).
Although the Amelogenin-based sex chromosome assay
has been frequently used in basic research and forensic
medicine, a false negative result for the detection of a Y-
chromosome has been documented when tumors of high
genomicinstabilityareanalyzed[13].Therefore,weanalyzed
two additional genes with X and Y homologues. The PRK
gene has its X and Y homologues located on Xp22.3
(PRKX) and Yp11.2 (PRKY)r e s p e c t i v e l y .T h ePRKY gene
is located approximately 0.35Mb centromeric to AMELY.T o
diﬀerentiatePRKX andPRKY,wedesignedaPCRreactionto
amplify exon 8 of the PRKX and PRKY genes, using a primer
set that spans a three-base pair deletion (Table 1)[ 14]. The
PRKY ampliﬁcation product is three bases shorter than the
PRKX product. The ZF gene has X and Y homologues
located at Xp22.1 (ZFX) and Yp11.2 (ZFY), respectively.Journal of Oncology 3
Choriocarcinoma
(a)
PSTT
(b)
ETT
(c)
Figure 1: Histological features of gestational trophoblastic neoplasms. Choriocarcinoma is characterized by biphasic growth pattern
composed of syncytiotrophoblast and mononucleate trophoblastic cells, forming vasculogenic mimicry. Placental site trophoblastic tumor
(PSTT) is composed of conﬂuent masses of neoplastic intermediate (extravillous) trophoblastic cells, inﬁltrating within smooth muscle
cells. Epithelioid trophoblastic tumor (ETT) contains neoplastic chorionic-type intermediate (extravillous) trophoblastic cells surrounding
an artery.
ZFY is located approximately 3.9Mb telomeric to AMELY.
To diﬀerentiate ZFX and ZFY, we designed a PCR reaction
to amplify exon 3 of the ZFX and ZFY genes, with the
primer set also spanning a 3-base pair deletion. In this
case, the ZFX product is 3 bases shorter than the ZFY
product.PCRampliﬁcationswerecarriedoutandtheprimer
sequences were listed in Table 1. Reactions were thermal
cycled using the touchdown protocol: 1 cycle of 95◦Cf o r2
minutes, 3 cycles each of 94◦C for 30 seconds, 64◦C, 61◦C,
or 58◦C for 30 seconds, and 70◦C for 30 seconds. This was
followed by 35 cycles of 94◦C for 30 seconds, 57◦Cf o r3 0
seconds and 70◦C for 30 seconds, and 1 cycle of 70◦Cf o r5
minutes. Products were analyzed by capillary electrophoresis
as described above.
3. Results andDiscussion
A total of 51 GTNs were histologically reviewed, including
19 choriocarcinomas, 17 ETTs, and 15 PSTTs (Table 2). Of
these samples, ETT17 contained a small area of choriocar-
cinoma and PSTT15 contained a focal ETT component.
Representative histologic features of the GTNs are illustrated
in Figure 1. All cases yielded informative results in at least
one of the gene markers utilized for the sex chromosome
genotyping. We found that all informative cases contained
a X-chromosomal complement while only ﬁve (10%, 95%
CI: 18.2%–1.8%) of 51 tumors harbored a Y chromosome
complement (Table 2). Speciﬁcally, Y-chromosomal signals
were detected in one (5%) of 19 choriocarcinomas, one
(7%) of 15 PSTTs, and three (18%) of 17 ETTs (Table 2).
Figure 2 illustrates the genotypes in representative speci-
mens. Of note, the genotypes were identical in genomic
DNA obtained from diﬀerent tissue blocks of the same
case. For those specimens with a Y-chromosome, all three
gene markers revealed consistent outcomes, although the
relative abundance of a Y gene versus an X gene varied. For
example, PSTT5 showed a small Y peak in both amelogenin
and ZF loci that could make the Y assignment equivocal
(Figure 2). However, by analyzing PRKY,w ec l e a r l yd e t e c t e d
ar o b u s tPRKY peak from the same specimen. Similarly,
ETT12 contained a relatively small amelogenin Y peak but
had signiﬁcantly large peaks at both PRKY and ZFY. These
ﬁndings indicate the variable eﬃciency of primers that
amplify the diﬀerent Y loci of the three genes on formalin-
ﬁxed paraﬃn tissues and underscore the importance to
include additional markers to assess the presence of Y-
chromosomal elements. The histopathological features in
those tumors with a Y-chromosome were indistinguishable
from those without a Y-chromosome. The percentage of
cases showing Y peaks is listed in Table 3.
The lack of a Y-chromosomal complement in the
majority of GTNs is intriguing and several theories can
account for this phenomenon. The most likely cause of
the phenomenon is that Y-chromosomal deletions have
no functional eﬀects on tumor progression [15]. In this
case, the absence of Y chromosome in GTNs may simply
reﬂect the fact that many GTNs develop from complete
hydatidiform moles of which approximately 90% contain a
karyotype of 46,XX due to fertilization of an “empty” ovum
(without nucleus) by a single haploid (23X) sperm followed
by haploid genome duplication [10, 11]. Thus, the GTNs
that develop from complete hydatidiform moles retain the
same sex chromosome assignment as their precursors and
do not harbor a Y-chromosome. While 90% of complete
hydatidiform moles arise from monospermy, approximately
10% are due to fertilization of an empty ovum with two
sperm. Half of these cases that arise from dispermy would
be expected to carry a Y-chromosome. Thus it could be
predicted that approximately 5% of complete hydatidiform4 Journal of Oncology
Table 2: The sex chromosome assignment in all the GTN samples.
Case Diagnosis AME PRK ZF Y peak
CC1 CC XX XX XX no
CC2 CC XX NA XX no
CC3 CC XX XX XX no
CC4 CC XX XX XX no
CC5 CC XX NA XX no
CC6 CC NA NA XX no
CC7 CC XX NA NA no
CC8 CC XX NA XX no
CC9 CC XX XX XX no
CC10 CC XX XX XX no
CC11 CC XY NA NA yes
CC12 CC XX XX XX no
CC13 CC XX XX XX no
CC14 CC NA NA XX no
CC15 CC NA XX NA no
CC16 CC XX NA XX no
CC17 CC XX XX XX no
CC18 CC XX XX NA no
CC19 CC XX XX XX no
ETT1 ETT XX XX XX no
ETT2 ETT XX XX XX no
ETT3 ETT XX NA XX no
ETT4 ETT XX XX XX no
ETT5 ETT XX XX XX no
ETT6 ETT XX XX XX no
ETT7 ETT NA XX XX no
ETT8 ETT XX XX XX no
ETT9 ETT XX XX XX no
ETT10 ETT XX XX XX no
ETT11 ETT XX XX NA no
ETT12 ETT XY∗ XY XY yes
ETT13 ETT XX XX XX no
ETT14 ETT XY XY XY yes
ETT15 ETT XX NA XX no
ETT16 ETT XX XX XX no
ETT17 ETT + CC XY∗ XY∗ XY∗ yes
PSTT1 PSTT XX XX XX no
PSTT2 PSTT NA NA XX no
PSTT3 PSTT XX XX XX no
PSTT4 PSTT XX XX XX no
PSTT5 PSTT XY∗ XY XY∗ yes
PSTT6 PSTT NA NA XX no
PSTT7 PSTT NA XX XX no
PSTT8 PSTT XX NA XX no
PSTT9 PSTT XX NA XX no
PSTT10 PSTT NA XX XX no
PSTT11 PSTT NA NA XX no
PSTT12 PSTT XX XX XX no
PSTT13 PSTT XX XX NA no
PSTT14 PSTT XX XX XX no
PSTT15 PSTT + ETT XX XX XX no
CC: CHORIOCARCINOMA, ETT: EPITHELIOID TROPHOBLASTIC TUMOR, PSTT: PLACENTAL SITE TROPHOBLASTIC TUMOR.Journal of Oncology 5
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Figure 2: Genotypes in representative trophoblastic tumor specimens. The presence of either the X or Y-chromosome in GTNs was
determined by the analysis of three genes that have X and Y homologues distinguishable by their PCR product size; Amelogenin Xa n d
Y( AMELX and AMELY), Protein Kinase Xa n dY( PRKX and PRKY), and Zinc Finger Xa n dY( ZFX and ZFY). Arrows denote the Y
chromosomal peaks.
Table 3: Summary of percentage of tumor cases positive for a Y
allele for at least one marker.
Choriocarcinoma ETT PSTT
Total case no. 19 17 15
With Y peaks 1 3 1
% with Y peaks 5.3% 17.6% 6.7%
CI (95%) 15.4%–0% 35.7%–0% 19.4%–0%
ETT: epithelioid trophoblastic tumor; PSTT: placental site trophoblastic
tumor; CI: conﬁdence interval.
moles, and their resulting choriocarcinomas, would carry a
Y-chromosome, which is exactly the percentage we obtained
in this study.
Although the above represents our favorite view, other
interpretations should also be indicated. It is possible that
Y-chromosome deletions have a functional implication in
the development of GTNs. In addition to GTNs developing
from trophoblastic cells of a female conceptus, it can be
speculated that GTNs arising from trophoblastic cells of a
maleconceptuswillundergoclonalselectionoftrophoblastic
cells with a deleted Y-chromosome due to their underlying
genomic instability. In both scenarios, it is assumed that
the presence of a Y-chromosome is not compatible with
tumor initiation, possibly due to potential growth-inhibitory
eﬀects conferred by the products of genes located in the Y-
chromosome. In support of this notion is the observation of
a small but unambiguous Y peak of AMELY, PRKY and ZFY
in the carefully dissected ETT17 (Figure 2). Also, previous
reports have demonstrated Y-chromosome loss in several
types of human cancer including prostate carcinoma, renal
cell carcinoma, acute promyelocytic leukemia, and head and
neck squamous carcinoma [15–18].
Lastly, the lack of Y-chromosome detection in other
studies may be the result of micro-deletions in the Y-
chromosomal regions analyzed, yielding a false negative
result. This technical pitfall has been well documented
in solid tumors when the amelogenin-based assay was
applied [13]. To overcome this problem, in this study we
have included two additional gene markers, PRK and ZF,
along with the standard amelogenin test. Similar to the
Amelogenin (AMEL) locus, the PRK, and ZF g e n e sh a v eX
and Y homologues located on Xp (PRKX and ZFX)a n dY p
(ZFX and ZFY). The PRKY and ZFY are located 3.9Mb
telomeric to AMELY and 0.35 Mb centromeric to AMELY,6 Journal of Oncology
respectively. The failure to detect any of the three genes of
the Y chromosome derives a more deﬁnitive conclusion and
suggests that the absence of Y-chromosome is not likely due
to somatic micro-deletions or microsatellite instability of the
Y-chromosome-associated loci in GTNs.
Among 51 GTNs analyzed, we detected Y alleles in ﬁve
tumors based on the presence of Y peaks in at least one of
the AMELY, PRKY and ZFY loci. Among these ﬁve tumors
was a PSTT. This ﬁnding is in contrast to a previous report
demonstrating that none of 13 PSTTs harbored the AMELY
[12]. The discrepancy is likely explained by the larger sample
sizeandtheadditionalYmarkersemployedinthisstudy.The
conclusion from the current study is also diﬀerent from our
previous report showing that approximately half of PSTTs
and ETTs contained the sex-determining region Y (SRY) on
Y chromosome [19]. In that study, a high cycle number of
PCR ampliﬁcation was used in order to detect a limited
source of genomic DNA from paraﬃn tissues, raising the
possibility of nonspeciﬁc ampliﬁcation from contaminants.
Thus, we believe that the results from the current study
are more deﬁnitive in determining the sex chromosome
assignment of GTNs.
In conclusion, this study provides a comprehensive
analysis of sex chromosome distributions in all types of
GTNs using three independent gene markers with diﬀering
PCR product lengths in the X and Y-chromosomes when
speciﬁc primer pairs are used. Our results, based on a
relatively large number of cases, clearly demonstrate the
presence of a distinct but low Y-chromosomal complement
in choriocarcinomas, PSTTs, and ETTs, that contributes to
an overall ﬁgure of approximately 10%. It is most likely
that the shortfall of Y chromosomal complements in GTNs
may simply be due to the genetic basis of their precursor
lesions, complete hydatidiform moles in which the majority
of cases had the genotype of XX [20]. In conclusion, our
results suggest that the majority of GTNs are preceded by
antecedent complete molar pregnancy, many of which may
be under recognized as the early complete moles usually lack
the characteristic histopathological features.
References
[1] I.-M. Shih, “Gestational trophoblastic neoplasia-pathogenesis
and potential therapeutic targets,” Lancet Oncology, vol. 8, no.
7, pp. 642–650, 2007.
[2] I.-M. Shih and R. J. Kurman, “The pathology of intermediate
trophoblastic tumors and tumor-like lesions,” International
Journal of Gynecological Pathology, vol. 20, no. 1, pp. 31–47,
2001.
[3] T.-L. Mao, R. J. Kurman, C.-C. Huang, M.-C. Lin, and I.-
M. Shih, “Immunohistochemistry of choriocarcinoma: an
aid in diﬀerential diagnosis and in elucidating pathogenesis,”
American Journal of Surgical Pathology, vol. 31, no. 11, pp.
1726–1732, 2007.
[4] A.Ilancheran,“Optimaltreatmentingestationaltrophoblastic
disease,” Annals of the Academy of Medicine Singapore, vol. 27,
no. 5, pp. 698–704, 1998.
[5] A. Hassadia, A. Gillespie, J. Tidy, et al., “Placental site
trophoblastic tumour: clinical features and management,”
Gynecologic Oncology, vol. 99, no. 3, pp. 603–607, 2005.
[6] A. J. Papadopoulos, M. Foskett, M. J. Seckl, et al., “Twenty-
ﬁve years’ clinical experience with placental site trophoblastic
tumors,” Journal of Reproductive Medicine for the Obstetrician
and Gynecologist, vol. 47, no. 6, pp. 460–464, 2002.
[7] I.-M. Shih and R. J. Kurman, “Epithelioid trophoblastic
tumor:aneoplasmdistinctfromchoriocarcinomaandplacen-
tal site trophoblastic tumor simulating carcinoma,” American
Journal of Surgical Pathology, vol. 22, no. 11, pp. 1393–1403,
1998.
[8] R. J. Kurman, R. E. Scully, and H. J. Norris, “Trophoblastic
pseudotumor of the uterus. An exaggerated form of ‘syncytial
endometritis’ simulating a malignant tumor,” Cancer, vol. 38,
no. 3, pp. 1214–1226, 1976.
[9] I.-M. Shih, “Trophogram, an immunohistochemistry-based
algorithmic approach, in the diﬀerential diagnosis of tro-
phoblastictumorsandtumorlikelesions,”AnnalsofDiagnostic
Pathology, vol. 11, no. 3, pp. 228–234, 2007.
[10] H. W. Li, S. W. Tsao, and A. N. Y. Cheung, “Current
understandings of the molecular genetics of gestational tro-
phoblastic diseases,” Placenta, vol. 23, no. 1, pp. 20–31, 2002.
[11] E. L. Garner, D. P. Goldstein, C. M. Feltmate, and R.
S. Berkowitz, “Gestational trophoblastic disease,” Clinical
Obstetrics and Gynecology, vol. 50, no. 1, pp. 112–122, 2007.
[12] P. Hui, H. L. Wang, P. Chu, et al., “Absence of Y chromosome
in human placental site trophoblastic tumor,” Modern Pathol-
ogy, vol. 20, no. 10, pp. 1055–1060, 2007.
[13] H. Vauhkonen, M. Hedman, M. Vauhkonen, P. Sipponen, and
A. Sajantila, “Typing of XY (male) genotype from malignant
neoplastic tissue by the amelogenin-based sex test,” Journal of
Forensic Sciences, vol. 49, no. 2, pp. 222–226, 2004.
[ 1 4 ]K .M .M u r p h y ,J .S .C o h e n ,A .G o o d r i c h ,P .P .L o n g ,
and C. A. Griﬃn, “Constitutional duplication of a region
of chromosome Yp encoding AMELY, PRKY, and TBL1Y:
implications for sex chromosome analysis and bone marrow
engraftment analysis,” Journal of Molecular Diagnostics, vol. 9,
no. 3, pp. 408–413, 2007.
[15] N. O. Bianchi, “Y chromosome structural and functional
changesinhumanmalignantdiseases,”Mutation Research,vol.
682, no. 1, pp. 21–27, 2009.
[16] Y. Wu, Y. Xue, and J. Pan, “Y-chromosome loss in acute
promyelocytic leukemia,” Cancer Genetics and Cytogenetics,
vol. 157, no. 1, pp. 90–91, 2005.
[17] M. Kujawski, M. Jarmuz, M. Rydzanicz, et al., “Frequent
chromosomeYlossinprimary,secondprimaryandmetastatic
squamous cell carcinomas of the head and neck region,”
Cancer Letters, vol. 208, no. 1, pp. 95–101, 2004.
[18] L. Bottarelli, C. Azzoni, F. Necchi, et al., “Sex chromosome
alterations associate with tumor progression in sporadic
colorectal carcinomas,” Clinical Cancer Research, vol. 13, no.
15, pp. 4365–4370, 2007.
[19] R. J. Oldt III, R. J. Kurman, and I.-M. Shih, “Molecular
genetic analysis of placental site trophoblastic tumors and
epithelioid trophoblastic tumors conﬁrms their trophoblastic
origin,” American Journal of Pathology, vol. 161, no. 3, pp.
1033–1037, 2002.
[ 2 0 ]R .A .P a t t i l l o ,S .S a s a k i ,K .P .K a t a y a m a ,M .R o e s l e r ,a n dR .
F. Mattingly, “Genesis of 46,XY hydatidiform mole,” American
Journal of Obstetrics and Gynecology, vol. 141, no. 1, pp. 104–
105, 1981.